Preventing Crohn's Disease Recurrence After Resection With Adalimumab: Role of Drug and Anti-Drug Antibody Levels

被引：0
|
作者：
Wright, Emily K.
Kamm, Michael A.
Selvaraj, Fabiyola
Princen, Fred
De Cruz, Peter
Hamilton, Amy L.
Ritchie, Kathryn
Krejany, Efrosinia O.
Gorelik, Alexandra
Liew, Danny
Prideaux, Lani
Lawrance, Ian C.
Andrews, Jane M.
Bampton, Peter A.
Jakobovits, Simon
Florin, Tim
Gibson, Peter R.
Debinski, Henry
Gearry, Richard B.
Macrae, Finlay A.
Samuel, Douglas
Kronborg, Ian
Radford-Smith, Graham L.
Selby, Warwick
Johnston, Michael J.
Woods, Rodney
Elliott, Peter R.
Bell, Sally
Brown, Steven J.
Connell, William
Desmond, Paul V.
Singh, Sharat
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1289
引用
收藏
页码：S849 / S849
页数：1
相关论文
共 50 条
  • [1] Preventing Crohn's Disease recurrence after resection with adalimumab: Role of drug and anti-drug antibody levels
    Wright, E.
    Kamm, M.
    Selvaraj, F.
    Princen, F.
    De Cruz, P.
    Hamilton, A.
    Ritchie, K.
    Krejany, E.
    Gorelik, A.
    Liew, D.
    Prideaux, L.
    Lawrance, I.
    Andrews, J.
    Bampton, P.
    Jakobovits, S.
    Florin, T.
    Gibson, P.
    Debinski, H.
    Gearry, R.
    Macrae, F.
    Samuel, D.
    Kronborg, I.
    Radford-Smith, G.
    Selby, W.
    Johnston, M.
    Woods, R.
    Elliott, P. R.
    Bell, S.
    Brown, S.
    Connell, W.
    Desmond, P.
    Singh, S.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S373 - S373
  • [2] Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn's disease
    Khoo, E.
    Lord, A.
    Hanigan, K.
    Croft, A.
    Radford-Smith, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S378 - S379
  • [3] Adalimumab Serum Concentrations or Anti-Drug Antibodies Do Not Influence Fatigue in Patients with Crohn's Disease
    Karlsen, Lars Normann
    Carlsen, Arne
    Omdal, Roald
    Aabakken, Lars
    Bolstad, Nils
    Lundin, Knut
    Grimstad, Tore
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S44 - S45
  • [4] Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
    Manca Ogrič
    Polona Žigon
    David Drobne
    Borut Štabuc
    Snezna Sodin-Semrl
    Saša Čučnik
    Sonja Praprotnik
    Immunologic Research, 2018, 66 : 726 - 736
  • [5] Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
    Ogric, Manca
    Zigon, Polona
    Drobne, David
    Stabuc, Borut
    Sodin-Semrl, Snezna
    Cucnik, Sasa
    Praprotnik, Sonja
    IMMUNOLOGIC RESEARCH, 2018, 66 (06) : 726 - 736
  • [6] Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
    Mazor, Y.
    Almog, R.
    Kopylov, U.
    Ben Hur, D.
    Blatt, A.
    Dahan, A.
    Waterman, M.
    Ben-Horin, S.
    Chowers, Y.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (06) : 620 - 628
  • [7] ADALIMUMAB SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 421 - 422
  • [8] Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
    Nakase, H.
    Motoya, S.
    Matsumoto, T.
    Watanabe, K.
    Hisamatsu, T.
    Yoshimura, N.
    Ishida, T.
    Kato, S.
    Nakagawa, T.
    Esaki, M.
    Nagahori, M.
    Matsui, T.
    Naito, Y.
    Kanai, T.
    Suzuki, Y.
    Nojima, M.
    Watanabe, M.
    Hibi, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (09) : 873 - 882
  • [9] Development of anti-drug monoclonal antibody panels against adalimumab and infliximab
    Suzuki, Takuo
    Tada, Minoru
    Ishii-Watabe, Akiko
    BIOLOGICALS, 2020, 63 : 39 - 47
  • [10] ANTI-TNF DRUG ANTIBODY LEVELS CORRELATE WITH POST-SURGICAL RECURRENCE IN CROHN'S DISEASE (CD)
    Pajot, Gregory
    Sunjaya, Dharma
    Ebner, Derek
    Ho, Ivan
    Eckmann, Jason
    Oblizajek, Nicholas R.
    Papadakis, Konstantinos A.
    GASTROENTEROLOGY, 2018, 154 (01) : S7 - S7
12345